Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.
Also called NCT02251067
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 165 participants
- Sponsor
- Vascular Pharmaceuticals, Inc.
- Registry
-
NCT02251067
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02251067. Randomized; double masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2017-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- VPI-2690B low dose
- Intervention (Drug)
- VPI-2690B medium dose
- Intervention (Drug)
- Placebo to match VPI-2690B
- Intervention (Drug)
- VPI-2690B high dose
- Lead sponsor
- Vascular Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct02251067- Content hash
7ebb4a205ea6a355609ef1c6a21551c987d7b895cb2d02656bd6f1b9433d8443